Blood cancer patients, already at high risk, often did not develop antibodies against COVID-19 from the first shot. But the booster and antibody therapy can provide a better shield.
Blood cancer patients, already at high risk, often did not develop antibodies against COVID-19 from the first shot. But the booster and antibody therapy can provide a better shield.